IMURAN (azathioprine sodium) by R-Pharm US is clinical pharmacology azathioprine is well absorbed following oral administration. Approved for active rheumatoid arthritis to reduce signs, symptoms, active rheumatoid arthritis (ra) to reduce signs and 2 more indications. First approved in 1974.
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
IMURAN (azathioprine sodium) is a small-molecule purine analog immunosuppressant used to reduce signs and symptoms of active rheumatoid arthritis. It works by being metabolized to 6-mercaptopurine, which is further converted to 6-thioguanine nucleotides that incorporate into DNA and suppress T-cell activation. The drug's efficacy depends on thiopurine S-methyltransferase (TPMT) and NUDT15 enzyme activity, making pharmacogenetic testing critical for safe dosing.
As a product approaching loss of exclusivity with minimal Part D spending ($434K in 2023), the brand team is likely small and focused on managing declining market share against modern JAK inhibitors and TNF-blockers.
CLINICAL PHARMACOLOGY Azathioprine is well absorbed following oral administration. Maximum serum radioactivity occurs at 1 to 2 hours after oral S-azathioprine and decays with a half-life of 5 hours. This is not an estimate of the half-life of azathioprine itself, but is the decay rate for all…
Worked on IMURAN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Special Drug Use Investigation for IMURAN (Azathioprine) Tablet (Pulmones Transplantation)
Drug Use Investigation for IMURAN (Azathioprine) Tablet (Hepatic Transplantation)
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moIMURAN offers extremely limited career opportunity, with zero linked job postings and minimal commercial activity ($434K annual spending). Working on this product would primarily involve managing a declining legacy portfolio in a small, understaffed team facing acute competition from modern immunosuppressants.